New Tests for Detection of Early Stage Lung Cancer

Lung Cancer

Cases of non-small-cell lung carcinoma (NSCLC) are not detected until they reach to the serious point that surgeries are not possible. In order to improve the outcomes from research, the researchers are working to develop the blood test for screening of lung cancer in the very early stage. A report in ‘The Journal of Molecular Diagnostics’ which explains new technology which is known as electric field-induced release and measurement (EFIRM) as highly sensitive in detecting two epidermal growth factor receptor (EGFR). Changes related to lung cancer in the blood of people suffering from early stage of the NSCLC. This way of treatment is relatively inexpensive and efficient to detect cancer.

Chemotherapy has numerous advantages than any other treatments and five-year survival for patients diagnosed less than 10 percent. The ability to diagnose cancer especially in stage 1 or 2. Early detection of cancer can reduce the rate of mortality due to NSCLC.

Charles M Strom, MD, Ph.D., and co-director of Center for Oral/Head and Neck Oncology Research center of the UCLA School of Dentistry, Los Angeles, Senior Vice President and Chief Medical Officer of EZLife Bio. He said the EFIRM is the most exciting development in the non-invasive liquid biopsy in the last few years. And early detection of lung cancer with affordable blood and saliva test that can save numerous lives globally.

Earlier, researchers have measured treatable EGFR mutations or changes in two blood samples of patients suffering from late-stage of NSCLC with the use of EFIRM technology. However, the current study, they studied the mutations which they found in samples of patients suffering from the early-stage disease.

The researchers have emphasized during the study that will not present the direct evidence which detects the EGFR mutations of an individual is predictive that patient has cancer. An EFIRM liquid biopsy will be more helpful in the guidance of treatment selection for the patients who cannot be treated with biopsy. With the EFIRM technique, patients’ tumor will be reduced significantly and to automate the process which increases sensitivity and offers mass screening.

Posted in ,

Rahul Pandita

Proficient in understanding the nuances of digital marketing, Rahul’s rising focus on the recent developments across leading industry verticals shine through his highly perceptive write-ups published on Fact.MR. Presenting before the world a clearer understanding regarding recent developments and ramifications, he offers a deeper understanding regarding the future growth prospects of the specific market.

Leave a Reply